Physician profile
Tracy E Tyson
NPI 1205865045
$669.69
in general payments reported to CMS, 2019-2025
12 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $441 · 2020: $179 · 2021: $49.00.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ironshore Pharmaceuticals INC. | $180.79 | 2019-2020 | |
| Neos Therapeutics, Lp | $114.74 | 2019-2021 | |
| Glaxosmithkline, LLC. | $102.89 | 2019-2020 | |
| Merck Sharp & Dohme LLC | $93.38 | 2019-2021 | |
| Tris Pharma INC | $40.33 | 2019-2020 | |
| Adlon Therapeutics L.P. | $28.85 | 2019-2021 | |
| Arbor Pharmaceuticals, INC. | $26.71 | 2019 | |
| Concordia Pharmaceuticals INC. | $26.16 | 2019 | |
| Pfizer INC. | $16.72 | 2019 | |
| Shire North American Group INC | $16.32 | 2019 | |
| Rhodes Pharmaceuticals L.P. | $11.56 | 2019 | |
| Kaleo, INC. | $11.24 | 2019 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Tracy Tyson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.